Back to Search
Start Over
Retrograde TrkAIII transport from ERGIC to ER: a re-localisation mechanism for oncogenic activity.
- Source :
-
Oncotarget [Oncotarget] 2015 Nov 03; Vol. 6 (34), pp. 35636-51. - Publication Year :
- 2015
-
Abstract
- In human SH-SY5Y neuroblastoma (NB) cells, nascent immature N-glycosylated 110kDa TrkA moves rapidly from the endoplasmic reticulum (ER) to the Golgi Network (GN), where it matures into the 140kDa receptor prior to being transported to the cell surface, creating GN and cell surface pools of inactive receptor maintained below the spontaneous activation threshold by a full compliment of inhibitory domains and endogenous PTPases. In contrast, the oncogenic alternative TrkAIII splice variant is not expressed at the cell surface but re-localises to intracellular membranes, within which it exhibits spontaneous ERGIC/COPI-associated activation and oncogenic Akt signalling. In this study, we characterise the mechanism responsible for TrkAIII re-localisation. Spontaneous TrkAIII activation, facilitated by D4 IG-like domain and N-glycosylation site omission, increases spontaneous activation potential by altering intracellular trafficking, inhibiting cell surface expression and eliminating an important inhibitory domain. TrkAIII, spontaneously activated within the permissive ERGIC/COPI compartment, rather than moving in an anterograde direction to the GN exhibits retrograde transport back to the ER, where it is inactivated. This sets-up self-perpetuating TrkAIII re-cycling between the ERGIC and ER, that ensures continual accumulation above the spontaneous activation threshold of the ERGIC/COPI compartment. This is reversed by TrkA tyrosine kinase inhibitors, which promote anterograde transport of inactivated TrkAIII to the GN, resulting in GN-associated TrkAIII maturation to a 120kDa species that is degraded at the proteasome.
- Subjects :
- Alternative Splicing genetics
Carcinogenesis genetics
Cell Line, Tumor
Glycosylation drug effects
Humans
Mutation genetics
Neuroblastoma drug therapy
Neuroblastoma genetics
Protein Kinase Inhibitors pharmacology
Protein Kinase Inhibitors therapeutic use
Protein Structure, Tertiary genetics
Protein Transport drug effects
Protein Transport genetics
Receptor, trkA genetics
Signal Transduction drug effects
Signal Transduction genetics
Endoplasmic Reticulum metabolism
Golgi Apparatus metabolism
Neuroblastoma metabolism
Oncogene Protein v-akt metabolism
Receptor, trkA metabolism
Subjects
Details
- Language :
- English
- ISSN :
- 1949-2553
- Volume :
- 6
- Issue :
- 34
- Database :
- MEDLINE
- Journal :
- Oncotarget
- Publication Type :
- Academic Journal
- Accession number :
- 26415233
- Full Text :
- https://doi.org/10.18632/oncotarget.5802